Pfizer (NYSE:PFE) Receives Daily Media Sentiment Rating of 0.13
Media coverage about Pfizer (NYSE:PFE) has trended somewhat positive on Tuesday, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pfizer earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.3642983664369 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern’s scoring:
- Will Pfizer Get Big Bucks for Advil and Other Household Names? (finance.yahoo.com)
- Notable Runner— Pfizer Inc. (PFE) – usstockjournal (usstockjournal.com)
- Worth Watching Stock – Pfizer Inc. (PFE) – android media cell (androidmediacell.com)
- Pfizer’s (PFE) Raised to Buy at recent price of $39.01 – Investorplace.com (investorplace.com)
- Today’s Research Reports on Stocks to Watch: AbbVie Inc. and Pfizer Inc. (finance.yahoo.com)
Pfizer (NYSE PFE) opened at $39.02 on Tuesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer has a 12 month low of $30.93 and a 12 month high of $39.43. The firm has a market cap of $232,527.17, a P/E ratio of 24.09, a PEG ratio of 2.41 and a beta of 1.01.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.49%. The ex-dividend date of this dividend is Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is 79.01%.
Pfizer declared that its Board of Directors has authorized a share buyback plan on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.
A number of research analysts recently commented on PFE shares. UBS Group set a $40.00 price objective on Pfizer and gave the company a “buy” rating in a report on Wednesday, December 6th. BMO Capital Markets reiterated a “buy” rating and issued a $39.00 price objective on shares of Pfizer in a report on Friday, November 10th. Vetr upgraded Pfizer from a “hold” rating to a “buy” rating and set a $38.82 price target on the stock in a research note on Thursday, November 23rd. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research note on Tuesday, October 3rd. Finally, Jefferies Group set a $39.00 price objective on Pfizer and gave the stock a “neutral” rating in a research report on Thursday, November 16th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $38.22.
In related news, insider Alexander R. Mackenzie sold 6,750 shares of Pfizer stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the sale, the insider now owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Rady A. Johnson sold 8,000 shares of Pfizer stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the sale, the executive vice president now directly owns 46,963 shares in the company, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. Insiders have sold a total of 29,450 shares of company stock worth $1,065,220 in the last 90 days. Company insiders own 0.06% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.